Key Points
-
Antineutrophil cytoplasmic autoantibodies (ANCAs) are associated with and probably cause pauci-immune systemic necrotizing small-vessel vasculitis and glomerulonephritis
-
ANCAs specific for proteinase 3 or myeloperoxidase occur with organ-limited disease, microscopic polyangiitis, granulomatosis with polyangiitis or eosinophilic granulomatosis with polyangiitis
-
ANCAs seem to cause vasculitis by activating circulating primed neutrophils and causing them to attach to, penetrate and damage vessel walls by undergoing respiratory burst, degranulation, NETosis, apoptosis and necrosis
-
ANCA-induced neutrophil activation also releases factors that activate the alternative complement pathway, which establishes a destructive inflammatory amplification loop that attracts and activates more neutrophils that, in turn, further activates the complement system
-
ANCA-associated granulomatosis might result from the same pathogenic sequence of events involving extravascular primed neutrophils and interstitial-fluid ANCAs, followed by a granulomatous reaction to wall off the resulting extravascular necrosis
Abstract
Antineutrophil cytoplasmic autoantibodies (ANCAs) are the probable cause of a distinct form of vasculitis that can be accompanied by necrotizing granulomatosis. Clinical and experimental evidence supports a pathogenesis that is driven by ANCA-induced activation of neutrophils and monocytes, producing destructive necrotizing vascular and extravascular inflammation. Pathogenic ANCAs can originate from precursor natural autoantibodies. Pathogenic transformation might be initiated by commensal or pathogenic microbes, legal or illegal drugs, exogenous or endogenous autoantigen complementary peptides, or dysregulated autoantigen expression. The ANCA autoimmune response is facilitated by insufficient T-cell and B-cell regulation. A putative pathogenic mechanism for vascular inflammation begins with ANCA-induced activation of primed neutrophils and monocytes leading to activation of the alternative complement pathway, which sets in motion an inflammatory amplification loop in the vessel wall that attracts and activates neutrophils with resultant respiratory burst, degranulation, extrusion of neutrophil extracellular traps, apoptosis and necrosis. The pathogenesis of extravascular granulomatosis is less clear, but a feasible scenario proposes that a prodromal infectious or allergic condition positions primed neutrophils in extravascular tissue in which they can be activated by ANCAs in interstitial fluid to produce extravascular necrotizing injury that would initiate an innate granulomatous inflammatory response to wall off the necrotic debris.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jennette, J. C. et al. Revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 65, 1–11 (2013).
Falk, R. J. & Jennette, J. C. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N. Engl. J. Med. 318, 1651–1657 (1988).
Goldschmeding, R. et al. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J. Clin. Invest. 4, 1577–1579 (1988).
Niles, J. L., McCluskey, T., Ahmad, M. F. & Amin Arnaout, M. A. Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood 74, 1888–1893 (1989).
Jennette, J. C., Hoidal, J. H. & Falk, R. J. Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. Blood 75, 2263–2264 (1990).
Lionaki, S. et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 64, 3452–3462 (2012).
Lyons, P. A. et al. Genetically distinct subsets within ANCA-associated vasculitis. N. Engl. J. Med. 367, 214–223 (2012).
Pendergraft, W. F. 3rd & Niles, J. L. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr. Opin. Rheumatol. 26, 42–49 (2014).
Graf, J. Rheumatic manifestations of cocaine use. Curr. Opin. Rheumatol. 25, 50–55 (2013).
Kain, R. et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat. Med. 14, 1088–1096 (2008).
Roth, A. J. et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J. Am. Soc. Nephrol. 23, 545–555 (2012).
Kawakami, T., Ishizu, A., Arimura, Y. & Soma, Y. Serum anti-lysosomal-associated membrane protein-2 antibody levels in cutaneous polyarteritis nodosa. Acta Derm. Venereol. 93, 70–73 (2013).
Kawakami, T., Takeuchi, S., Arimura, Y. & Soma, Y. Elevated antilysosomal-associated membrane protein-2 antibody levels in patients with adult Henoch-Schönlein purpura. Br. J. Dermatol. 166, 1206–1212 (2012).
Roozendaal, C. et al. Does analysis of the antigenic specificities of anti-neutrophil cytoplasmic antibodies contribute to their clinical significance in the inflammatory bowel diseases? Scand. J. Gastroenterol. 34, 1123–1131 (1999).
Ooi, C. J., Lim, B. L., Cheong, W. K., Ling, A. E. & Ng, H. S. Antineutrophil cytoplasmic antibodies (ANCAs) in patients with inflammatory bowel disease show no correlation with proteinase 3, lactoferrin, myeloperoxidase, elastase, cathepsin G and lysozyme: a Singapore study. Ann. Acad. Med. Singapore 29, 704–707 (2000).
Mahler, M. et al. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. Clin. Chim. Acta. 424, 267–273 (2013).
Hervier, B. et al. Systemic lupus erythematosus associated with ANCA-associated vasculitis: an overlapping syndrome? Rheumatol. Int. 32, 3285–3290 (2012).
Levy, J. B., Hammad, T., Coulthart, A., Dougan, T. & Pusey, C. D. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 66, 1535–1540 (2004).
Jennette, J. C. & Thomas, D. B. in Heptinstall's Pathology of the Kidney 6th edn (eds Jennette, J. C. et al.) 643–674 (Lippincott Williams & Wilkins, 2007).
Jennette, J. C. Nomenclature and classification of vasculitis: lessons learned from granulomatosis with polyangiitis (Wegner's granulomatosis). Clin. Exp. Immunol. 164 (Suppl. 1), 7–10 (2011).
Mark, E. J., Matsubara, O., Tan-Liu, N. S. & Fienberg, R. The pulmonary biopsy in the early diagnosis of Wegener's (pathergic) granulomatosis: a study based on 35 open lung biopsies. Hum. Pathol. 19, 1065–1071 (1988).
Jennette, J. C., Xiao, H., Falk, R. & Gasim, A. M. Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies. Contrib. Nephrol. 169, 211–220 (2011).
Rastaldi, M. P. et al. Glomerular monocyte-macrophage features in ANCA-positive renal vasculitis and cryoglobulinemic nephritis. J. Am. Soc. Nephrol. 11, 2036–2043 (2000).
Weidner, S., Carl, M., Riess, R. & Rupprecht, H. D. Histologic analysis of renal leukocyte infiltration in antineutrophil cytoplasmic antibody-associated vasculitis: importance of monocyte and neutrophil infiltration in tissue damage. Arthritis Rheum. 50, 3651–3657 (2004).
Cunningham, M. A. et al. Prominence of cell-mediated immunity effectors in “pauci-immune” glomerulonephritis. J. Am. Soc. Nephrol. 10, 499–506 (1999).
Bajema, I. M., Hagen, E. C., de Heer, E., van der Woude, F. J. & Bruijn, J. A. Colocalization of ANCA-antigens and fibrinoid necrosis in ANCA-associated vasculitis. Kidney Int. 60, 2025–2030 (2001).
Kessenbrock, K. et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 15, 623–625 (2009).
Abreu-Velez, A. M., Smith, J. G. Jr & Howard, M. S. Presence of neutrophil extracellular traps and antineutrophil cytoplasmic antibodies associated with vasculitides. North Am. J. Med. Sci. 1, 309–313 (2009).
Kambas, K. et al. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-203430 (2013).
Lamprecht, P. & Gross, W. L. Current knowledge on cellular interactions in the WG-granuloma. Clin. Exp. Rheumatol. 25 (Suppl. 44), S49–S51 (2007).
Jennette, J. C. & Falk, R. J. The rise and fall of horror autotoxicus and forbidden clones. Kidney Int. 78, 533–535 (2010).
Cui, Z., Zhao, M. H., Segelmark, M. & Hellmark, T. Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. Kidney Int. 78, 590–597 (2010).
Olson, S. W. et al. Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J. Am. Soc. Nephrol. 22, 1946–1952 (2011).
Xu, P. C., Cui, Z., Chen, M., Hellmark, T. & Zhao, M. H. Comparison of characteristics of natural autoantibodies against myeloperoxidase and anti-myeloperoxidase autoantibodies from patients with microscopic polyangiitis. Rheumatology (Oxford) 50, 1236–1243 (2011).
Roth, A. J. et al. ANCA epitope specificity determines pathogenicity, detectability and clinical predictive value. J. Clin. Invest. 123, 1773–1783 (2013).
Olson, S. W. et al. Relation between asymptomatic proteinase 3 antibodies and future granulomatosis with polyangiitis. Clin. J. Am. Soc. Nephrol. 8, 1312–1318 (2013).
Popa, E. R., Stegeman, C. A., Kallenberg, C. G. & Tervaert, J. W. Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res. 4, 77–79 (2002).
Laudien, M. et al. Nasal carriage of Staphylococcus aureus and endonasal activity in Wegener's granulomatosis as compared to rheumatoid arthritis and chronic rhinosinusitis with nasal polyps. Clin. Exp. Rheumatol. 28 (Suppl. 57), 51–55 (2010).
Davies, D. J., Moran, J. E., Niall, J. F. & Ryan, G. B. Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br. Med. J. (Clin. Res. Ed.) 285, 606 (1982).
Pendergraft, W. F. et al. Autoimmunity is triggered by cPR-3(105–201), a protein complementary to the autoantigen proteinase 3. Nat. Med. 10, 72–79 (2004).
Preston, G. A., Pendergraft, W. F. 3rd & Falk, R. J. New insights that link microbes with the generation of antineutrophil cytoplasmic autoantibodies: the theory of autoantigen complementarity. Curr. Opin. Nephrol. Hypertens. 14, 217–222 (2005).
Heal, J. R., Roberts, G. W., Raynes, J. G., Bhakoo, A. & Miller, A. D. Specific interactions between sense and complementary peptides: the basis for the proteomic code. Chembiochem. 3, 136–151 (2002).
Mekler, L. B. On the specific mutual interaction of amino acid residues of polypeptide chains and amino acid residues with codons. Oncology 27, 286–288 (1973).
Yang, J. J. et al. ANCA patients have T cells responsive to complementary PR-3 autoantigen. Kidney Int. 74, 1159–1169 (2008).
Badhwar, A. K., Simmons, J., Jennette, J. C., Falk, R. J. & Preston, G. A. Characterization of an antisense transcript from the proteinase-3 gene locus in patients with ANCA-vasculitis utilizing strand-specific RT-PCR and 5′RACE [abstract]. J. Am. Soc. Nephrol. 19, 188A (2008).
Cao, Y. et al. DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. J. Am. Soc. Nephrol. 22, 1161–1167 (2011).
Shoenfeld, Y. Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J. 8, 1296–1301 (1994).
Yang, J. J. et al. Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. J. Am. Soc. Nephrol. 15, 2103–2114 (2004).
Ciavatta, D. J. et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J. Clin. Invest. 120, 3209–3219 (2010).
Durant, S. et al. Apoptosis-induced proteinase 3 membrane expression is independent from degranulation. J. Leukoc. Biol. 75, 87–98 (2004).
Kantari, C. et al. Proteinase 3, the Wegener autoantigen, is externalized during neutrophil apoptosis: evidence for a functional association with phospholipid scramblase 1 and interference with macrophage phagocytosis. Blood 110, 4086–4095 (2007).
Morgan, M. D. et al. Patients with Wegener's granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. Immunology 130, 64–73 (2010).
Rimbert, M. et al. Decreased numbers of blood dendritic cells and defective function of regulatory T cells in antineutrophil cytoplasmic antibody-associated vasculitis. PLoS ONE 6, e18734 (2011).
Free, M. E. et al. Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective TREG cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum. 65, 1922–1933 (2013).
Wilde, B et al. Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis. Rheumatology (Oxford) 7, 1188–1197 (2012).
Bunch, D. O. et al. Decreased CD5+ B cells in active ANCA vasculitis and relapse after rituximab. Clin. J. Am. Soc. Nephrol. 8, 382–391 (2013).
Wilde B. et al. Regulatory B cells in ANCA-associated vasculitis. Ann. Rheum. Dis. 72, 1416–1419 (2013).
Scapini, P., Bazzoni, F. & Cassatella, M. A. Regulation of B-cell-activating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophils. Immunol. Letters 116, 1–6 (2008).
Krumbholz, M. et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. J. Autoimmun. 25, 298–302 (2005).
Sanders, J. S., Huitma, M. G., Kallenberg, C. G. & Stegeman, C. A. Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse. Ann. Rheum. Dis. 65, 1484–1489 (2006).
Nagai, M. et al. Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: association with disease activity. Nephron Clin. Pract. 118, c339–c345 (2011).
Bader, L., Koldingsnes, W. & Nossent, J. B-lymphocyte activating factor levels are increased in patients with Wegener's granulomatosis and inversely correlated with ANCA titer. Clin. Rheumatol. 29, 1031–1035 (2010).
Falk, R. J., Terrell, R. S., Charles, L. A. & Jennette, J. C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl Acad. Sci. USA 87, 4115–4119 (1990).
Huugen, D. et al. Aggravation of anti-myeloperoxidase antibody induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor α. Am. J. Pathol. 167, 47–58 (2005).
Schreiber, A. et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J. Am. Soc. Nephrol. 20, 289–298 (2009).
Porges, A. J. et al. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fcγ RIIa. J. Immunol. 153, 1271–1280 (1994).
Kocher, M., Siegel, M. E., Edberg, J. C. & Kimberly, R. P. Cross-linking of Fcγ receptor IIa and Fcγ receptor IIIb induces different proadhesive phenotypes on human neutrophils. J. Immunol. 159, 3940–3948 (1997).
Kettritz, R., Jennette, J. C. & Falk, R. J. Cross-linking of ANCA-antigens stimulates superoxide release by human neutrophils. J. Am. Soc. Nephrol. 8, 386–394 (1997).
Williams, J. M. et al. Activation of the Gi heterotrimeric G protein by ANCA IgG F(ab')2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG. J. Am. Soc. Nephrol. 14, 661–669 (2003).
Kettritz, R., Schreiber, A., Luft, F. C. & Haller, H. Role of mitogen-activated protein kinases in activation of human neutrophils by antineutrophil cytoplasmic antibodies. J. Am. Soc. Nephrol. 12, 37–46 (2001).
van der Veen, B. S. et al. Effects of p38 mitogen-activated protein kinase inhibition on anti-neutrophil cytoplasmic autoantibody pathogenicity in vitro and in vivo. Ann. Rheum. Dis. 70, 356–365 (2011).
Hao, J., Meng, L. Q., Xu, P. C., Chen, M. & Zhao, M. H. p38MAPK, ERK and PI3K signaling pathways are involved in C5a-primed neutrophils for ANCA-mediated activation. PLoS ONE 7, e38317 (2012).
Charles, L. A., Caldas, M. L., Falk, R. J., Terrell, R. S. & Jennette, J. C. Antibodies against granule proteins activate neutrophils in vitro. J. Leukoc. Biol. 50, 539–546 (1991).
Csernok, E., Ernst, M., Schmitt, W., Bainton, D. F. & Gross, W. L. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin. Exp. Immunol. 95, 244–250 (1994).
Ewert, B. H., Jennette, J. C. & Falk, R. J. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int. 41, 375–383 (1992).
Savage, C. O., Gaskin, G., Pusey, C. D. & Pearson, J. D. Myeloperoxidase binds to vascular endothelial cells, is recognized by ANCA and can enhance complement dependent cytotoxicity. Adv. Exp. Med. Biol. 336, 121–123 (1993).
Ewert, B. H., Becker, M. E., Jennette, J. C. & Falk, R. J. Antimyeloperoxidase antibodies induce neutrophil adherence to cultured human endothelial cells. Ren. Fail. 17, 125–133 (1995).
Lu, X., Garfield, A., Rainger, G. E., Savage, C. O. & Nash, G. B. Mediation of endothelial cell damage by serine proteases, but not superoxide released from antineutrophil cytoplasmic antibody-stimulated neutrophils. Arthritis Rheum. 54, 1619–1628 (2006).
Gupta, A. K. et al. Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death. FEBS Letters 584, 3193–3197 (2010).
Casselman, B. L., Kilgore, K. S., Miller, B. F. & Warren, J. S. Antibodies to neutrophil cytoplasmic antigens induce monocyte chemoattractant protein-1 secretion from human monocytes. J. Lab. Clin. Med. 126, 495–502 (1995).
Ralston, D. R., Marsh, C. B., Lowe, M. P. & Wewers, M. D. Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, α1-antitrypsin, and Fcγ receptors. J. Clin. Invest. 100, 1416–1424 (1997).
Muller Kobold, A. C., Kallenberg, C. G. & Tervaert, J. W. Monocyte activation in patients with Wegener's granulomatosis. Ann. Rheum. Dis. 58, 237–245 (1999).
Arimura, Y. et al. The role of myeloperoxidase and myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCAs) in the pathogenesis of human MPO-ANCA-associated glomerulonephritis. Clin. Exp. Nephrol. 17, 634–637 (2013).
Xiao, H. et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110, 955–963 (2002).
Jennette, J. C., Xiao, H., Falk, R. & Gasim, A. M. Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies. Contrib. Nephrol. 169, 211–220 (2011).
van Timmeren, M. M. & Heeringa, P. Pathogenesis of ANCA-associated vasculitis: recent insights from animal models. Curr. Opin. Rheumatol. 24, 8–14 (2012).
Salama, A. D. & Little, M. A. Animal models of antineutrophil cytoplasm antibody-associated vasculitis. Curr. Opin. Rheumatol. 24, 1–7 (2012).
van der Geld, Y. M. et al. Rats and mice immunized with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes. Ann. Rheum. Dis. 66, 1679–1682 (2007).
Pfister, H. et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 104, 1411–1418 (2004).
Primo, V. C. et al. Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis. Clin. Exp. Immunol. 159, 327–337 (2010).
Little, M. A. et al. Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS ONE 7, e28626 (2012).
Xiao, H. et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am. J. Pathol. 167, 39–45 (2005).
Schreiber, A., Xiao, H., Falk, R. J. & Jennette, J. C. Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. J. Am. Soc. Nephrol. 17, 3355–3364 (2006).
Xiao, H. et al. Genetically determined severity of anti-myeloperoxidase glomerulonephritis. Am. J. Pathol. 8, 139–160 (2013).
van Timmeren, M. M. et al. IgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritis. J. Am. Soc. Nephrol. 21, 1103–1114 (2010).
Xiao, H., Schreiber, A., Heeringa, P., Falk, R. J. & Jennette, J. C. Alternative complement pathway in the pathogenesis of disease mediated by antineutrophil cytoplasmic autoantibodies. Am. J. Pathol. 170, 52–64 (2007).
Huugen, D. et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 71, 646–654 (2007).
Xiao, H. et al. C5a receptor (CD88) blockade protects against MPO-ANCA glomerulonephritis. J. Am. Soc. Nephrol. 25, 225–231 (2014).
Xing, G. Q. et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J. Clin. Immunol. 29, 282–291 (2009).
Yuan, J. et al. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res. Ther. 14, R140 (2012).
Gou, S. J., Yuan, J., Chen, M., Yu, F. & Zhao, M. H. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 83, 129–137 (2012).
Klinger, H. Grenzformen der periarteriitis nodosa [German]. Frankf. Z. Pathol. 42, 455–480 (1931).
Wegener, F. Über generalisierte septische Gefässerkrankungen [German]. Verh. Deut. Pathol. Ges. 29, 202–210 (1936).
Wegener, F. Über eine eigenartige rhinogene Granulomatose mit besonderer Beteiligung des Arteriensystems und der Nieren [German]. Beitr. Pathol. Anat. 102, 30–68 (1939).
Churg, J. & Strauss, L. Allergic granulomatosis, allergic antiitis, and periarteritis nodosa. Am. J. Pathol. 27, 277–294 (1951).
Petersen, H. J. & Smith, A. M. The role of the innate immune system in granulomatous disorders. Front. Immunol. 4, 120 (2013).
Voswinkel, J., Müller, A. & Lamprecht, P. Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann. NY Acad. Sci. 1051, 12–19 (2005).
Acknowledgements
The authors are supported by a grant from the NIH National Institute of Diabetes and Digestive and Kidney Diseases (P01-DK058335-11).
Author information
Authors and Affiliations
Contributions
J.C.J. researched data for the article, and both authors contributed equally to discussions of content, writing and review/editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
J.C.J. has acted as a consultant for Amicus Therapeutics, Genentech, GlaxoSmithKline and Protalix BioTherapeutics, and has undertaken research in collaboration with ChemoCentryx. R.J.F. declares no competing interests.
Rights and permissions
About this article
Cite this article
Jennette, J., Falk, R. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 10, 463–473 (2014). https://doi.org/10.1038/nrrheum.2014.103
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2014.103
This article is cited by
-
Antineutrophil cytoplasmic antibody-associated vasculitis classification by cluster analysis based on clinical phenotypes: a single-center retrospective cohort study
Clinical Rheumatology (2024)
-
Childhood-Onset ANCA- Associated Vasculitis: single center experience from Central California
Pediatric Rheumatology (2023)
-
A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
Trials (2023)
-
Selective deficiency of UCP-1 and adropin may lead to different subtypes of anti-neutrophil cytoplasmic antibody-associated vasculitis
Genes & Immunity (2023)
-
Clinical advances in immunotherapy for immune-mediated glomerular diseases
Clinical and Experimental Medicine (2023)